Search research articles
Contact Us
Filters
Showing results (1081-1090 of 1,210) with videos related to
Page
of 121
Sort By:
Inflammatory Bowel Diseases
|
July 22, 2015
Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization
Benjamin Click, Eric J Vargas, Alyce M Anderson, et al.
Cancer
|
November 21, 2019
A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
Alice Y Ho, Christopher A Barker, Brittany B Arnold, et al.
Cancer Research
|
April 17, 2002
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer
Jun Luo, Shan Zha, Wesley R Gage, et al.
Microbiome
|
January 17, 2018
Multi-omics differentially classify disease state and treatment outcome in pediatric Crohn's disease
Gavin M Douglas, Richard Hansen, Casey M A Jones, et al.
BMJ Oncology
|
June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data
Helena M Earl, Louise Hiller, Janet A Dunn, et al.
Inflammatory Bowel Diseases
|
October 19, 2016
Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation
Abhik Bhattacharya, Bhavana B Rao, Ioannis E Koutroubakis, et al.
Plos One
|
July 9, 2016
The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study
Leila Dorling, Siddhartha Kar, Kyriaki Michailidou, et al.
The New England Journal of Medicine
|
March 19, 2004
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
John P Neoptolemos, Deborah D Stocken, Helmut Friess, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 4, 2019
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma
Lara A Dunn, Nadeem Riaz, Matthew G Fury, et al.
British Journal of Cancer
|
September 18, 2008
NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life
H M Earl, L Hiller, J A Dunn, et al.
Page
of 121
Search research articles
Search
Showing results (1081-1090 of 1,210) with videos related to
Sort By:
Page
of 121
Inflammatory Bowel Diseases
|
July 22, 2015
Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization
Benjamin Click, Eric J Vargas, Alyce M Anderson, et al.
Cancer
|
November 21, 2019
A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
Alice Y Ho, Christopher A Barker, Brittany B Arnold, et al.
Cancer Research
|
April 17, 2002
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer
Jun Luo, Shan Zha, Wesley R Gage, et al.
Microbiome
|
January 17, 2018
Multi-omics differentially classify disease state and treatment outcome in pediatric Crohn's disease
Gavin M Douglas, Richard Hansen, Casey M A Jones, et al.
BMJ Oncology
|
June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data
Helena M Earl, Louise Hiller, Janet A Dunn, et al.
Inflammatory Bowel Diseases
|
October 19, 2016
Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation
Abhik Bhattacharya, Bhavana B Rao, Ioannis E Koutroubakis, et al.
Plos One
|
July 9, 2016
The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study
Leila Dorling, Siddhartha Kar, Kyriaki Michailidou, et al.
The New England Journal of Medicine
|
March 19, 2004
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
John P Neoptolemos, Deborah D Stocken, Helmut Friess, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 4, 2019
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma
Lara A Dunn, Nadeem Riaz, Matthew G Fury, et al.
British Journal of Cancer
|
September 18, 2008
NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life
H M Earl, L Hiller, J A Dunn, et al.
Page
of 121